Edition:
United States

GlycoMimetics Inc (GLYC.OQ)

GLYC.OQ on NASDAQ Stock Exchange Global Market

25.01USD
16 Feb 2018
Change (% chg)

-- (--)
Prev Close
$25.01
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
172,737
52-wk High
$26.05
52-wk Low
$3.83

Latest Key Developments (Source: Significant Developments)

Glycomimetics Enters Agreement With Hovon To Initiate Study Startup Activities For Planned Clinical Trial Of GMI-1271 And Decitabine
Thursday, 8 Feb 2018 09:00am EST 

Feb 8 (Reuters) - Glycomimetics Inc ::GLYCOMIMETICS ENTERS INTO AGREEMENT WITH HOVON TO INITIATE STUDY STARTUP ACTIVITIES FOR PLANNED CLINICAL TRIAL OF GMI-1271 AND DECITABINE IN PATIENTS WITH NEWLY DIAGNOSED ACUTE MYELOID LEUKEMIA (AML) WHO ARE UNFIT FOR CHEMOTHERAPY.GLYCOMIMETICS INC - ‍ON TRACK TO DISCLOSE DETAILS FOR DESIGN OF PHASE 3 TRIAL IN RELAPSED/REFRACTORY AML PATIENTS DURING 2017 YEAR-END EARNINGS CALL.GLYCOMIMETICS INC - ‍ HOVON INTENDS TO ENROLL APPROXIMATELY 140 PATIENTS IN CLINICAL TRIAL OF GMI-1271 AND DECITABINE​.  Full Article

GlycoMimetics qtrly loss per share $‍0.24
Wednesday, 8 Nov 2017 07:30am EST 

Nov 8 (Reuters) - Glycomimetics Inc :Glycomimetics reports program updates and third quarter 2017 results.Glycomimetics inc - ‍phase 3 clinical trial of rivipansel on track for completion in second half of 2018​.Glycomimetics inc qtrly loss per share $‍0.24​.Glycomimetics inc - ‍research and development expenses decreased slightly to $5.8 million for quarter ended september 30, 2017 as compared to $5.9 million​.  Full Article

GlycoMimetics says files for mixed shelf of upto $250 mln
Thursday, 28 Sep 2017 05:59pm EDT 

Sept 28 (Reuters) - GlycoMimetics Inc :GlycoMimetics Inc says files for mixed shelf of upto $250.0 million - SEC filing‍​.  Full Article

Glycomimetics presents updated data from ongoing phase 1/2 clinical trial of GMI-1271 at ASCO
Monday, 5 Jun 2017 07:00am EDT 

June 5 (Reuters) - Glycomimetics Inc :Glycomimetics presents updated data from ongoing phase 1/2 clinical trial of GMI-1271 in patients with acute myeloid leukemia at ASCO 2017 annual meeting.Glycomimetics Inc says GMI-1271 continues to be well tolerated in combination with induction chemotherapy.Glycomimetics -remission rates continue to be higher than historical controls & induction-related mortality continues to be lower than historical controls.Glycomimetics Inc - in study only one case of severe (grade 3/4) mucositis reported among 79 patients receiving high-intensity induction chemotherapy.Glycomimetics Inc - relapsed/refractory patients with more blasts expressing e-selectin ligand were more likely to achieve complete response in study.  Full Article

Glycomimetics announces pricing of public offering of common stock
Wednesday, 24 May 2017 08:00am EDT 

May 24 (Reuters) - Glycomimetics Inc :Glycomimetics announces pricing of public offering of common stock.Says public offering of 7.00 million common shares priced at $11.50per share.  Full Article

Glycomimetics Inc terminates sales agreement with Cowen and Company
Wednesday, 24 May 2017 07:25am EDT 

May 24 (Reuters) - Glycomimetics Inc :Glycomimetics Inc - co terminated its sales agreement, dated March 1, 2016, with Cowen and Company.  Full Article

Glycomimetics announces proposed public offering of common stock
Monday, 22 May 2017 04:01pm EDT 

May 22 (Reuters) - Glycomimetics Inc :Glycomimetics announces proposed public offering of common stock.Intends to offer and sell, subject to market conditions, 6 million shares of common stock in an underwritten public offering.To use net proceeds to complete its ongoing phase 1/2 clinical trial of GMI-1271 in patients with acute myeloid leukemia (AML).Also intends to use net proceeds to complete its ongoing phase 1 clinical trial of GMI-1271 in patients with multiple myeloma (MM).  Full Article

Glycomimetics reports supportive biomarker data from early-stage trial of GMI-1271
Thursday, 18 May 2017 06:30am EDT 

May 18 (Reuters) - GlycoMimetics Inc -:GlycoMimetics announces high overall response rates, low induction mortality, promising initial survival outcomes, and supportive biomarker data from phase 1/2 trial of GMI-1271 in AML.  Full Article

Glycomimetics reports qtrly net loss per share of $0.34
Monday, 8 May 2017 09:00am EDT 

May 8 (Reuters) - Glycomimetics Inc :Glycomimetics reports program updates and first quarter 2017 results.Qtrly net loss per share $0.34.Qtrly loss per share $0.34.Phase 3 program to evaluate Rivipansel for vaso-occlusive sickle cell crisis, according to Pfizer, remains on track for completion in H2 2018.  Full Article

GlycoMimetics qtrly net loss per share $0.34
Monday, 8 May 2017 09:00am EDT 

May 8 (Reuters) - Glycomimetics Inc :Glycomimetics reports program updates and first quarter 2017 results.Qtrly net loss per share $0.34.Glycomimetics inc qtrly loss per share $0.34.Glycomimetics-Phase 3 program to evaluate rivipansel for vaso-occlusive sickle cell crisis, according to pfizer, remains on track for completion in h2 2018.  Full Article

BRIEF-Glycomimetics Enters Agreement With Hovon To Initiate Study Startup Activities For Planned Clinical Trial Of GMI-1271 And Decitabine

* GLYCOMIMETICS ENTERS INTO AGREEMENT WITH HOVON TO INITIATE STUDY STARTUP ACTIVITIES FOR PLANNED CLINICAL TRIAL OF GMI-1271 AND DECITABINE IN PATIENTS WITH NEWLY DIAGNOSED ACUTE MYELOID LEUKEMIA (AML) WHO ARE UNFIT FOR CHEMOTHERAPY